Pharmaceuticals
EU orphan medicines regulation failed
Two decades of EU market protection of ‘orphan’ (rare disease) medicines have greatly benefitted the industry. According to research by The Investigative Desk, published in …
Pharmaceuticals
EMA rewrites medicine approval policy
New innovative medicines should be made available to European citizens more quickly. That is why the European Medicines Agency updates the process for market authorisation. …
Pharmaceuticals
Evergreening the world’s most profitable medicine
Even after the expiration of Humira’s patent protection, AbbVie, the pharmaceutical company, almost completely fended off biosimilar competition for this blockbuster medicine in the Netherlands. …
